Physician profile
Peter Wm Forgach
NPI 1427051515
$3,680.46
in general payments reported to CMS, 2019-2025
22 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $86.32 · 2021: $199 · 2022: $667 · 2023: $786 · 2024: $733 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,903.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,551.60 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $430.63 | 2022-2025 | Syfovre |
| Genentech USA, INC. | $336.74 | 2019-2024 | Vabysmo |
| Astellas Pharma US INC | $249.63 | 2023-2025 | Izervay |
| Alimera Sciences, INC. | $195.08 | 2019-2023 | Iluvien |
| Novartis Pharmaceuticals Corporation | $168.70 | 2019-2020 | |
| Oyster Point Pharma, INC. | $125.86 | 2022-2024 | Tyrvaya |
| Eyepoint US, INC. | $109.94 | 2019-2023 | |
| Alcon Vision LLC | $99.74 | 2020-2023 | Simbrinza |
| Bausch & Lomb Americas INC. | $96.47 | 2022-2024 | Vyzulta, Xipere |
| Biotissue Holdings INC. | $73.90 | 2022-2025 | |
| Sight Sciences, INC. | $30.37 | 2021 | |
| Ani Pharmaceuticals, INC. | $28.22 | 2025 | Yutiq |
| Tarsus Pharmaceuticals, INC. | $27.88 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23.27 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $23.11 | 2023 | Xelpros, Cequa |
| Coherus Oncology, INC. | $23.11 | 2023 | |
| Sandoz INC. | $21.98 | 2024 | Cimerli |
| Mallinckrodt Hospital Products INC. | $19.75 | 2022 | |
| Dompe US, INC. | $17.35 | 2022 | |
| Alcon Research LLC | $14.85 | 2019 | |
| Horizon Therapeutics Plc | $12.28 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Forgach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.